Muscle involvement is found in most critical patients admitted to the intensive care unit (ICU). Diaphragmatic muscle alteration, initially included in this category, has been differentiated in recent years, and a specific type of muscular dysfunction has been shown to occur in patients undergoing mechanical ventilation. We found this muscle dysfunction to appear in this subgroup of patients shortly after the start of mechanical ventilation, observing it to be mainly associated with certain control modes, and also with sepsis and/or multi-organ failure. Although the specific etiology of process is unknown, the muscle presents oxidative stress and mitochondrial changes. These cause changes in protein turnover, resulting in atrophy and impaired contractility, and leading to impaired functionality. The term 'ventilator-induced diaphragm dysfunction' was first coined by Vassilakopoulos et al. in 2004 , and this phenomenon, along with injury cause by over-distention of the lung and barotrauma, represents a challenge in the daily life of ventilated patients.
Introduction
Mechanical ventilation (MV) has been used throughout history as a basic tool in the treatment of patients with respiratory failure, and as a means of improving prognosis. Almost 40% of mechanically ventilated patients have difficulties during MV weaning, due to multiple factors. A delay in weaning can prolong the stay in the intensive care unit (ICU) and lead to a poorer prognosis [1] [2] [3] and a 12% increase in mortality compared to patients with no weaning problems. 4 In the last 20 years or so, attention has focused on the study of ventilation-induced diaphragm dysfunction (VIDD) 5 as one of the complications associated with MV. This term refers to diaphragm dysfunction that occurs soon after initiating MV. 6 VIDD worsens prognosis and is associated with extubation failure, which in turn prolongs MV [7] [8] [9] [10] [11] [12] and increases the risk of mortality. [13] [14] [15] [16] At present, however, diaphragm function is not routinely monitored in many units, suggesting that this entity may be systematically underdiagnosed. 17 
Ventilation-induced Diaphragm Dysfunction
Although respiratory muscle weakness could be considered part of the overall muscle involvement in a critical patient, the last 10 years have seen the emergence of the concept of VIDD. 18 This term refers to diaphragm muscle dysfunction caused by the negative effect of the MV itself, that can occur along with or independently of involvement of the rest of the musculature.
Although earlier studies described how complete diaphragm inactivity induced in patients receiving controlled modality ventilation leads to a rapid, progressive loss of diaphragm function, 19, 20 it was not until 2004 that Vassilakopoulos first coined the term VIDD, 18 defined as a progressive loss of diaphragm muscle strength that occurs soon after starting MV. 8, 21 The condition affects up to 65% of ventilated patients, 7 and is clinically significant due to its early onset.
Pathophysiology of Ventilator-induced Diaphragm Dysfunction
Several studies have shown that the use of controlled MV (CMV), in which the patient makes no inspiratory effort and the diaphragm is not actively contracted, can lead to contractile dysfunction and diaphragm atrophy within 24 h in both laboratory animals and humans. 20, 22, 23 Atrophied muscles lose strength and the diaphragm excursion is diminished due to the reduction in the cross-sectional area of the muscle fibers, manifesting as a loss of inspiratory capacity. 7, 24 Below we discuss the physiopathological principles associated with VIDD.
Diaphragmatic Atrophy
CMV-induced diaphragm atrophy occurs extremely rapidly. 22 Significant diaphragm atrophy can be observed in laboratory animals within the first 12-18 h of starting CMV, with no sign of peripheral atrophy. 25 Thus, MV-induced diaphragm atrophy is significantly greater than the atrophy caused by skeletal muscle disuse. 22 Levine et al. encountered similar findings in patients receiving CMV for 18-69 h, and showed a significant reduction of around 53%-57% compared to healthy volunteers in both type 1 and type 2 fibers in cross-sectional diaphragm biopsies. 23 Changes in Muscle Fiber Ultrastructure CMV causes time-dependent changes in the ultrastructure of the diaphragm muscle fibers. 19, 26, 27 First, areas containing abnormal myofibrils due to myofibrillar disorganization and Z-band changes appear. 19 This is followed by the appearance of areas of muscle fiber regeneration, with no signs of inflammation. 27 Finally, if MV is prolonged (over 3 days), cytoplasmic lipid vacuoles increase, probably due to an autophagic process. [27] [28] [29] 
Contractile Dysfunction
In 1994, Le Bourdelles et al. were the first to describe, in an animal model, the appearance of contractile dysfunction 48 h after starting CMV. 30 Prolonged MV causes progressive, time-dependent loss of diaphragm strength. 20 As with atrophy, this reduction in diaphragm strength can be seen within 12 h of CMV. 31, 32 Several studies have shown that the maximum inspiratory pressure peak is lower in patients receiving prolonged MV compared to controls. 18 
Changes in Protein Synthesis
Diaphragmatic atrophy and dysfunction associated with the use of CMV occur primarily due to a reduction in protein synthesis and an increase in proteolysis. 23, 33 Diaphragmatic protein synthesis can fall by 30% after only 6 h of MV. 33 Increased proteolysis is associated with the activation of protease pathways (calpain, capase-3, and ubiquitin-proteasome system), apoptosis pathways, and activation of autophagy. 34, 35 Hooijman et al. analyzed the activity of the ubiquitin-proteasome pathway in diaphragm biopsy samples from patients ventilated during thoracic surgery. Patients with a significant increase in this pathway showed a loss of approximately 25% of both slow and fast twitch diaphragm muscle fibers on cross-sectional biopsy, and reduced contractile strength. 36, 37 Increased Oxidative Stress During CMV, changes occur in mitochondrial morphology causing altered functioning and excessive creation of reactive oxygen species (ROS). Increased oxidative stress triggers the activation of calpain and caspase-3 pathways in the diaphragm. 34, 38, 39 The very early appearance (at 18 h) of reduced diaphragm muscle fiber diameter and evidence of oxidative stress phenomena and activation of proteases has been confirmed in brain-dead donor patients. 23 Prolonged MV also leads to diminished antioxidant capacity in the diaphragm, reflected by reduced glutathione levels, CuZn superoxide dismutase, and peroxidase glutathione activity. 40 
Effect of Critical Disease on Diaphragm Function
Although the consequences of CMV-induced diaphragm dysfunction are known, the pathways leading to these changes have yet to be described. Diaphragm inactivity induces progressive, time-dependent diaphragm atrophy. 6, 25 However, other factors also play a part in increasing the risk of VIDD and greater diaphragmatic involvement. Sepsis and multiorgan failure are the factors most robustly associated with diaphragm dysfunction, which is more severe in septic patients than in patients with shock due to other causes. 7 The proinflammatory situation that occurs in these diseases may reduce protein synthesis and increase proteolysis, which itself may trigger an acute loss of muscle mass. 9, 41 Concomitant factors and pharmacological treatment (corticosteroids or muscle relaxants, for example) may exacerbate VIDD. Two studies examining muscle relaxants in mice confirmed that the use of rocuronium exacerbates MV-induced contractile dysfunction. 42, 43 Data on the effect of corticosteroids on diaphragm function are contradictory. Sassoon et al. found an association between the administration of high-dose methylprednisolone and reduced inspiratory force in an experimental model. 44 However, the group led by Maes showed that administration of a single dose of corticosteroids reduced the deleterious effect of MV. 42 Experimental data have associated high blood glucose levels with loss of diaphragm strength, related with an increase in oxidative stress processes. 45 
Invasive Mechanical Ventilation Modalities and Ventilation-induced Diaphragm Dysfunction
The diaphragmatic changes characteristic of VIDD caused by controlled modality ventilation have been demonstrated in animal models and humans, and onset is early. 8, 23, 2633, 46, 47 This modality, in which the diaphragm remains totally inactive, can cause greater atrophy and contractile dysfunction, leading to loss of diaphragm strength. Unlike CMV modalities, uncontrolled MV requires the patient to make the inspiratory effort. Several authors have suggested that this action may prevent the deleterious effects of CMV. Doering et al. showed that the prolonged use of high levels of pressure in support pressure modalities caused atrophy and contractile dysfunction. 48 In contrast, Futier et al. suggested that assisted MV and pressure support would reduce proteolysis and increase protein synthesis in the diaphragm. 49 Gayan-Ramírez et al. demonstrated that short periods of spontaneous breathing during CMV delays the effects of this modality on the diaphragm, adding credence to the idea that diaphragm disuse is the main causative factor of VIDD. 50 Changes in the configuration of the diaphragm may be prevented by maintaining inspiratory effort levels provided by pressure support. 51 
Non-invasive Mechanical Ventilation and High-flow Oxygen Therapy
Only 1 study has evaluated diaphragm functionality after starting non-invasive MV (NIMV). The authors conclude that the force generated by the diaphragm falls after initiating ventilation, and that this is related with high levels of pressure support. 52 NIMV applies positive pressure, with a certain degree of flattening and muscle stretching, which may be the origin of the dysfunction.
High-flow oxygen therapy provides gas at up to 60 l/min with the corresponding FIO2, generating low levels of positive pressure and ventilatory pattern changes, with increased circulating volume, 53 but to date, no studies have analyzed its impact on diaphragm function. However, as this respiratory support system ensures the patient's diaphragm is fully activated at all times, it probably has little impact on muscle strength.
Diagnosis and Monitoring
Very few UCIs conduct routine monitoring of respiratory muscle function, either because its importance is underestimated or because the technical difficulties are considerable. 17 VIDD diagnosis is initially based on suspicion in mechanically ventilated patients whose intercurrent difficulties have been solved but who present problems on MV weaning. In the case of VIDD, no relationship has been established between clinical examination and the degree of diaphragm dysfunction, 54 so additional examinations are needed for diagnosis (Table 1) . Below is a list of some of the best tests for evaluating diaphragm function. Some are only useful in research; others can be used in clinical practice.
Transdiaphragmatic and Esophageal Pressure
Esophageal pressure is a good indicator of pleural pressure 55, 56 and is used together with gastric pressure to calculate transdiaphragmatic pressure (Pdi). Pdi is simply the difference between pleural pressure and abdominal pressure, and is the basis for calculating diaphragm strength. 7, 13, 57, 58 The gold standard in patients who cannot collaborate in the test is to calculate Pdi via cervical magnetic stimulation of the phrenic nerve. 8, 54, 59 However, this is an invasive technique that is not available in most ICUs.
A reduction in Pdi can be detected soon after starting MV, 59 and continues logarithmically as the duration of MV increases. 8 Demoule et al. published a study 7 that showed how Pdi values lower than 11 cm H 2 O on the first day of ICU admission predicted a poor prognosis, high mortality (49%), and longer MV. 7, 14 Gilbert's index, calculated using Pdi ( Gastric pressure/ Pdi) during a normal inhalation, evaluates the contribution of the diaphragm to respiratory pressure during quiet breathing. 60 Watson et al., using diaphragm ultrasonography and Pdi in patients undergoing cardiothoracic surgery, found a good correlation between low diaphragm excursion and low Gilbert indices. 61 P 0.1 P 0.1 measures the negative pressure generated by the patient against an artificial airway in the first 100 ms of an inspiratory effort, reflecting the neuromuscular impulse transmitted by the phrenic nerve. 62 Though not without limitations,it is a measurement of central stimulus and an indicator of diaphragm function. 63, 64 This measurement has been included in artificial respirators, and, as such, it has become a clinical variable accessible at the bedside. 65 
Ultrasonography
The need for early diagnosis with an easily available, noninvasive technique explains the growing use of ultrasonography in the evaluation and follow-up of diaphragm function and inspiratory effort. 66 Its limitations include inter-and intra-observer variability and the fact that the dynamic study (diaphragm excursion) can only be conducted in patients without MV. [67] [68] [69] [70] However, several studies using ultrasonography have shown good accuracy and reproducibility for evaluating diaphragm function, both in healthy volunteers and in critical patients. 52, 69 Diaphragm thickness (as a sign of atrophy), shortening fraction, and diaphragm mobility studies (as a sign of diaphragm activity) are the parameters most commonly evaluated by ultrasonography.
Diaphragm Excursion
To evaluate diaphragm motion, a 3.5-5 MHz probe must be positioned below the rib cage at the level of the mid-clavicular line, directing the ultrasound beam perpendicularly toward the posterior third of the hemidiaphragm. During inhalation, the normal diaphragm moves down, and thus approaches the transducer (Fig. 1) .
Normal values in healthy non-ventilated patients differ between men and women (18 ± 3 and 16 ± 3 mm, respectively), 69 similarly to baseline values in mechanically ventilated patients. 71 Diaphragm dysfunction is defined as an excursion of less than 10 mm or a negative excursion (or paradoxical movement). These values are also good predictors of failure to wean. 72 
Diaphragm Thickness
Diaphragm thickness depends on muscle mass, and is correlated with forced vital capacity. 73 Reduced diaphragm thickness is associated with low amplitudes on electromyography, and may indicate the presence of atrophy. 23, 74 Diaphragm thickness can be quantified simply using ultrasonography, with the right hemidiaphragm, via the hepatic window, being more accessible than the left. 51 To determine thickness, a 10-12 MHz probe, positioned perpendicularly over the 9th-10th intercostal space in the anterior axillary line, is used to observe part of the zone of apposition of diaphragm to rib cage. In this area, the diaphragm is seen as 3 parallel layers of differing density (pleura, diaphragm, and peritoneum). 51, 70 Diaphragm thickness is measured by M-mode or with a 2D image during non-forced expiration (Fig. 2) . Normal diaphragm thickness in ventilated patients is 2.4 ± 0.8 mm, with atrophy defined as values below 2 mm. 51 Ratios of 1.8 are considered normal, with a lower accepted limit of 1.2. 68 
Variation in Diaphragm Thickness
Variation in diaphragm thickness can be calculated using Mmode with the formula indicated in Fig. 3 . Diaphragm thickness variation can be used as an indicator of diaphragm capacity to generate pressure. 52, 75 A variation of <20% may be considered as a predictor for failure to wean 54 and is a better prediction than the Tobin index. 76 Grosu et al. found a daily reduction of 6% in diaphragm thickness in the first 48 h after starting ventilation with assisted modalities. 67 In the study of Schepens et al., in which most patients were receiving CMV, a 10.9% loss of thickness was reported. 71 Although no direct association was found between diaphragm thickness and CMV, the data show a greater loss of thickness in patients primarily ventilated using the controlled modality.
In MV patients, changes in diaphragm thickness, unlike diaphragm excursion, may really reflect active diaphragm contraction. This was demonstrated by Goligher et al., who did not observe variations in relaxed patients but did see changes in healthy volunteers and patients undergoing different MV methods. 74 In non-ventilated patients, thickness variation has been shown to be directly related with lung volumes 70, 77, 78 and with maximum inspiratory pressure 79 and, as such, could be an indirect measurement of contractile activity and the diaphragm workload.
Laboratory Markers
No relationship between the appearance of respiratory muscle atrophy and increased muscle enzymes, such as creatine kinase and myoglobin, has been observed in blood tests. 9 An increase in skeletal protein troponin I may, in the future, be used as a marker of diaphragm muscle damage. [80] [81] [82] Conclusions Diaphragm dysfunction in the mechanically ventilated patient is a disorder that is still undefined and underdiagnosed. It appears early after the initiation of MV and is associated with risk factors such as sepsis and multiorgan failure. It affects a high percentage of patients and leads to extubation failure.
Future studies are needed to determine the initial processes that trigger protein changes and to develop non-invasive techniques, accessible at the bedside, in order to establish an early diagnosis: in this respect, ultrasonography is playing an increasingly important role.
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